VCYT News & Events

Veracyte announced the U.S. commercial launch of the Prosigna Breast Risk of Recurrence, ROR, test. The Prosigna test determines a patient's ROR score and estimates the 10-year probability of distant recurrence, providing prognostic insight into how a patient's cancer may behave over time. These insights also help guide treatment decisions, including predicting whether high risk patients are likely to benefit from chemotherapy or may safely achieve optimal outcomes with endocrine therapy alone, enabling clinicians to make personalized care plans for their patients. The Prosigna test will be available to order starting June 8, 2026.

Veracyte announced results from the Enzamet trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate test identifies which men with metastatic prostate cancer benefit from adding the chemotherapy docetaxel to standard hormonal therapy, known as triplet therapy, and who can safely avoid it, providing the first Level 1B 1 evidence for a genomic test guiding this decision. Results showed: Patients with higher Decipher scores and high-volume disease who received triplet therapy had clinically meaningful better survival compared to those on standard hormonal therapy alone. Patients with lower Decipher scores showed no benefit from adding chemotherapy, suggesting it may be safely avoided. The treatment-by-biomarker interaction was statistically significant, providing Level 1B evidence for the test's predictive value. Patients with higher Decipher scores who received triplet therapy had more aggressive disease features, yet achieved comparable survival to lower-risk patients on doublet therapy, suggesting chemotherapy offset the poor prognostic effects of aggressive disease biology.

Veracyte announced that its TrueMRD Monitoring Test has received coverage from the Centers for Medicare & Medicaid Services', CMS, Molecular Diagnostics Services Program for patients with muscle-invasive bladder cancer, MIBC. The TrueMRD Test is covered for recurrence monitoring following definitive treatment with curative intent in patients with MIBC. It will be available for clinicians to order on June 1, 2026, marking the commercial launch of Veracyte's first molecular residual disease, MRD, offering and the only commercially available truly whole-genome MRD test to come to market, expanding the company's reach into cancer recurrence monitoring.